Sign In
Buy ZLDPF
$42.89
-1.86 (-4.16%)
At Close: Jun 23, 2026
Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
01:00am, Friday, 19'th Jun 2026
Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company's obesity strategy While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on
Drugmakers race to find a place in the next wave of obesity drugs
08:00am, Saturday, 13'th Jun 2026
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent Am
Zealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot's Side Effects
07:23am, Monday, 08'th Jun 2026
Nearly a fifth of patients exited the survodutide trial due to adverse gastrointestinal events such as nausea, vomiting and diarrhea, Boehringer said.
Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial
04:44am, Monday, 08'th Jun 2026
Zealand Pharma lost a fifth of its market value on Monday after a late-stage trial found many patients stopped taking a weight-loss drug due to tolerability problems.
Zealand Pharma shares drop 20% as obesity drug side effects raise concerns
03:41am, Monday, 08'th Jun 2026
Zealand Pharma's shares fell more than 20% in early trade on Monday after trial data showed its obesity drug survodutide had worse side effects and higher patient �
Is Zealand Pharma AS (ZLDPF) Stock Undervalued Right Now?
10:41am, Tuesday, 12'th May 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Zealand Pharma A/S (ZLDPY) Q1 2026 Earnings Call Transcript
02:51pm, Thursday, 07'th May 2026
Zealand Pharma A/S (ZLDPY) Q1 2026 Earnings Call Transcript
Zealand Pharma A/S (ZLDPF) Reports Q1 Loss, Lags Revenue Estimates
08:10am, Thursday, 07'th May 2026
Zealand Pharma A/S (ZLDPF) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $1.57. This compares to a loss of $0.67 per share a year ago.
Zealand Pharma posts smaller-than-expected Q1 loss as obesity drugs advance
01:10am, Thursday, 07'th May 2026
Danish drug developer Zealand Pharma reported a smaller-than-expected first-quarter operating loss on Thursday, boosted by strong momentum in its obesity drug pipeline, �
Comparing Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Zealand Pharma A/S (OTCMKTS:ZLDPF)
04:10am, Saturday, 18'th Apr 2026
Brainstorm Cell Therapeutics (NASDAQ: BCLI - Get Free Report) and Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) are both medical companies, but which is the superior business? We will contrast
Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Recommendation of “Moderate Buy” by Brokerages
04:49am, Thursday, 02'nd Apr 2026
Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat reports. Five e
Zealand Pharma A/S (ZLDPF) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
04:22pm, Wednesday, 11'th Mar 2026
Zealand Pharma A/S (ZLDPF) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Disappointing weight-loss-trial results from Zealand Pharma sends shares tumbling
08:52am, Friday, 06'th Mar 2026
Zealand Pharma obesity drug showed disappointing weight loss in a Phase 2 trial.
Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
03:19am, Friday, 06'th Mar 2026
The company said the data supported further development of the drug in chronic weight management on its own or in combination with other drugs due to its tolerability.
Zealand Pharma A/S (ZLDPF) Discusses Top Line Phase II Results for ZUPREME-1 Trial of Petrelintide in Obesity Transcript
08:25pm, Thursday, 05'th Mar 2026
Zealand Pharma A/S (ZLDPF) Discusses Top Line Phase II Results for ZUPREME-1 Trial of Petrelintide in Obesity Transcript
